In a report released yesterday, Edward Nash from Canaccord Genuity maintained a Buy rating on Exagen (XGN), with a price target of $25.00. The company’s shares closed last Tuesday at $13.54.
According to TipRanks.com, Nash is a 3-star analyst with an average return of 4.3% and a 39.4% success rate. Nash covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Galmed Pharmaceuticals, and Oramed Pharmaceuticals.
Exagen has an analyst consensus of Strong Buy, with a price target consensus of $24.50, implying a 95.4% upside from current levels. In a report issued on May 12, BTIG also reiterated a Buy rating on the stock with a $23.00 price target.
See today’s analyst top recommended stocks >>
Based on Exagen’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $10.59 million and GAAP net loss of $6.21 million. In comparison, last year the company earned revenue of $9.58 million and had a GAAP net loss of $5.56 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exagen Diagnostics Inc was incorporated under the laws of the state of New Mexico in 2002. The Company is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets four products under its Avise brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. It processed approximately 9,300 patient specimens for its diagnostic product line, Avise SLE. It markets and sells solutions to community rheumatologists.
